At what enterprise value was DOMUSVI acquired in 2017?

During the acquisition of DOMUSVI by ICG / MANAGEMENT & PRIVATE INVESTORS in 2017, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DOMUSVI when it was acquired by ICG / MANAGEMENT & PRIVATE INVESTORS?

The estimated EV/EBITDA multiple for DOMUSVI is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was DOMUSVI acquired by ICG / MANAGEMENT & PRIVATE INVESTORS?

DOMUSVI was acquired by ICG / MANAGEMENT & PRIVATE INVESTORS in 2017.

What was the revenue of DOMUSVI at the time of the deal?

The revenue of DOMUSVI at the time of the deal is estimated to be in the range of 750M - 1.3b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of DOMUSVI during the acquisition?

DOMUSVI's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DOMUSVI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DOMUSVI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.paipartners.com/mediaitem/pai-partners-enters-exclusive-negotiations-sale-majority-stake-domusvi/

← DATABASE

Home Database Healthcare & PharmaDOMUSVI

06/2017

DOMUSVI acquired by ICG & MANAGEMENT & PRIVATE INVESTORS

FRANCE Health Providers / Healthcare Facilities / Nursing Homes EV 1b - 4b EUR

Context

ICG and founder Yves Journel have entered into exclusive negotiations to acquire the majority stake in DomusVi from PAI Partners. The transaction follows a preemptive bid by ICG that successfully bypassed a formal auction process involving major international investors and sovereign funds. This deal marks a significant change in scale for the group, which was valued at less than €650 million in 2014. The acquisition is structured to maintain the existing high-yield bond financing, as the continued presence of ICG and the founder in the capital prevents the activation of change-of-control repayment clauses. The strategic rationale centers on pursuing the international expansion of the group, particularly in markets like Spain, where the recent integration of SARquavitae has already propelled the company to a leadership position. The partnership intends to bridge the gap with major competitors such as Orpea and Korian-Medica by leveraging DomusVi's strong expertise in specialized care and home services.

In the past, the company underwent an LBO led by Pai Partners in 2014, and continued an active consolidation strategy by notably acquiring Sarquavitae (2016).

DOMUSVI, which reported an EBITDA margin of LOGIN in 2017, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

DomusVi stands as a leading international provider of high-quality elderly care and specialized services. The group operates an extensive cross-border network across Europe and Latin America, encompassing medicalized nursing homes, mental health facilities, and home care agencies. The entity actively executes a targeted buy-and-build strategy aimed at securing and strengthening its premier position within its domestic market. DomusVi’s value proposition is built upon a multi-disciplinary approach to dependency and senior care, seamlessly integrating medicalized residential care, specialized disability centers, and home assistance solutions to deliver a comprehensive support ecosystem for seniors and their families.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2017

2016

Other operations with DOMUSVI

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2021	ICG / MANAGEMENT & PRIVATE INVESTORS	DOMUSVI	FRANCE	Health Providers	DomusVi completed a major capital reorganization, described as a "jumbo-LBO". This transaction allowed founder Yves Journel to increase his ownership from 30% to 49%, while ICG remains a key controlling partner
03/2019	DOMUSVI	RESIDALYA	FRANCE	Health Providers	DomusVi entered into exclusive negotiations to acquire 100% of the capital of Residalya, in a move designed to significantly densify its territorial coverage within France. The transaction allowed DomusVi to absorb 35 additional facilities and roughly 2,630 beds, bringing its total capacity to over 17,000 beds and narrowing the gap with its primary market competitors
10/2016	DOMUSVI	SARQUAVITAE	SPAIN	Health Providers	DomusVi has successfully acquired its Spanish competitor SARquavitae, previously held by a consortium of investment funds including Palamon Capital Partners and G Square Capital. This transformative build-up operation allows the group to become the number one player in the Spanish elderly care market
06/2014	PAI PARTNERS	DOMUSVI	FRANCE	Health Providers	PAI Partners has entered into exclusive negotiations to take control of DomusVi, the third largest French player in the private nursing home sector. Upon completion of the transaction, PAI is expected to hold 70% of the capital alongside an associated fund

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 750M - 1.3b EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DOMUSVI by ICG / MANAGEMENT & PRIVATE INVESTORS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: icg